Fostamatinib
- Generic Name
- Fostamatinib
- Brand Names
- Tavalisse, Tavlesse
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26FN6O9P
- CAS Number
- 901119-35-5
- Unique Ingredient Identifier
- SQ8A3S5101
- Background
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP . Fostamatinib has also been granted orphan drug status by the FDA .
Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.
- Indication
用于治疗对既往治疗反应不足的慢性免疫性血小板减少症（ITP）成年患者的血小板减少症。
- Associated Conditions
- Chronic immune thrombocytopenia
Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Holdsworth House Medical Practice
- Target Recruit Count
- 20
- Registration Number
- NCT05040698
- Locations
- 🇦🇺
Holdsworth House Medical Practice, Sydney, New South Wales, Australia
Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy with Hypomethylating Agents
- Conditions
- Refractory Myelodysplastic SyndromeRefractory Chronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT05030675
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Novel Experimental COVID-19 Therapies Affecting Host Response
- Conditions
- COVID-19SARS-CoV-2 InfectionCoronavirus Infection
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Sean Collins
- Target Recruit Count
- 1060
- Registration Number
- NCT04924660
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Ponce de Leon Clinical Research Site, Atlanta, Georgia, United States
🇺🇸Emory St. Joseph's Hospital, Atlanta, Georgia, United States
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT04904276
- Locations
- 🇺🇸
Saint Agnes Hospital, Baltimore, Maryland, United States
🇺🇸New York Medical College, Valhalla, New York, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
- Conditions
- SARS PneumoniaPneumoniaSARS (Severe Acute Respiratory Syndrome)Pneumonia, ViralSARS-Associated Coronavirus as Cause of Disease Classified ElsewhereCovid19
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 280
- Registration Number
- NCT04629703
- Locations
- 🇧🇷
Hospital Luxenburgo-Associação Mário Penna, Belo Horizonte, Minas Gerais, Brazil
🇧🇷Irmandade da Santa Casa de Misericórdia de Porto Alegre - ISCMPA, Porto Alegre, Rio Grande Do Sul, Brazil
🇺🇸Alternative Research Associates, LLC, Miami, Florida, United States
Inflammatory Signal Inhibitors for COVID-19 (MATIS)
- Conditions
- Covid19CoronavirusPneumonia
- Interventions
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 456
- Registration Number
- NCT04581954
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
Fostamatinib for Hospitalized Adults With COVID-19
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2022-03-02
- Target Recruit Count
- 59
- Registration Number
- NCT04579393
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸INOVA Health Systems, Falls Church, Virginia, United States
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
- Conditions
- MyelofibrosisThrombocytopenia
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 3
- Registration Number
- NCT04543279
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT04138927
- Locations
- 🇺🇸
University of Southern California - Janice and Robert Hall Clinical Trials Biospecimen Laboratory, Los Angeles, California, United States
🇺🇸Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT04132050
- Locations
- 🇯🇵
Research Site, Multiple Locations, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.